// App-Quantinova.ai

OT2-01-20 : Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)

Researchers

Presenter

  • B Lim

Principal Investigators

  • T Helgason

  • KR Hess

  • H Piwnica-Worms

  • W Yang

  • BE Adrada

  • GM Rauch

  • M Gilcrease

  • FW Symmans

  • L Huo

  • EA Mittendorf

  • A Thompson

  • M-TL Stacy

  • T Debu

  • NT Ueno

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

Biomarkers

  • Mitogen-activated protein kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating tumor cells

  • Programmed death-ligand 1

  • Epidermal growth factor

  • Epidermal growth factor receptor

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • Carboplatin

  • panitumumab

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved